Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Dose Escalation and Expansion Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

NCT04868877 is registered in ClinicalTrials.gov with Merus B.V. as lead sponsor.

NCT NCT04868877
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04868877 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Dose Escalation and Expansion Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
Lead sponsor
Merus B.V.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
April 28, 2021
Completion date
March 31, 2027
Enrollment
194 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, esophageal squamous cell carcinoma, gastric cancer, head and neck squamous cell carcinoma, non-small cell lung cancer metastatic